

**FDA Genetic Toxicology Workshop**  
**How many doses of an Ames-positive/Mutagenic (DNA Reactive) Drug can be**  
**safely administered to Healthy Subjects?**

**November 4, 2019**

**FDA White Oak Campus – Building 2 (CSU), Room 2031**

8:00 – 8:30 a.m.

Registration

**Presentations**

8:30 – 9:00 a.m.

Introduction: How many doses of an Ames-Positive (DNA Reactive) Drug can be safely administered to Healthy Subjects?

Dr. Timothy W. Robison, CDER, FDA

9:00 – 9:25 a.m.

FDA Requirements for the Protection of Healthy Subjects in Phase 1 Clinical Trials

Dr. Kevin Prohaska, CDER, FDA

9:30 – 9:50 a.m.

Considerations for a Genotoxic API in Clinical Trials: Healthy Subjects or Patients?

Dr. Bob Dorsam, CDER, Office of Generics, FDA

9:50 – 10:35 a.m.

Literature review for data relevant to administering one or a few doses of a DNA reactive drug to healthy subjects

Drs. Dayton Petibone and Jennifer Shemansky, NCTR, FDA

10:35 – 10:50 a.m.

**Break**

10:50 – 11:25 a.m.

Do the Steps between Genotoxin and Cancer Create Thresholds of Dose or Time?

Dr. Douglas Brash, Yale University

11:25 a.m. – Noon

Setting Allowable Exposures to Ames-positive Candidate Drugs

Dr. Kenny Crump, Louisiana Tech University

12:00 – 1:00 p.m.

**LUNCH**

***Panel Discussion***

1:00 – 4:00 p.m.

**Moderator**

Dr. Aisar Atrakchi  
CDER, FDA

**Panelists**

- Dr. Alan Boobis  
Professor of Toxicology (emeritus), Imperial College London
  
- Dr. Douglas Brash  
Professor of Therapeutic Radiology and Dermatology, Yale University
  
- Dr. Kenny Crump  
Professor of Mathematics and Statistics, Louisiana Tech University
  
- Dr. Robert Heflich  
Director, Division of Genetic and Molecular Toxicology  
National Center for Toxicologic Research, FDA
  
- Dr. Timothy McGovern  
Office of Drug Evaluation, Associate Director of Pharmacology and  
Toxicology, CDER, FDA
  
- Dr. Miriam C. Poirier  
Scientist Emeritus, National Cancer Institute, NIH
  
- Dr. Kevin A. Prohaska  
Captain (U.S. Public Health Service Corps):  
Senior Medical Policy Advisor/Bioethics Consultant, FDA
  
- Dr. Errol Zeiger  
Private Consultant/Formerly of the National Toxicology Program

4:00 p.m.

**ADJOURN**